Advancing Clinical Decision Making by Reverse Translating Tumor & T-Cell Biomarker Signals Into Actionable TIL Response Frameworks

• Leveraging PD-1-positive TIL selection strategies as surrogate biomarkers of tumor reactivity in breast cancer solid tumor
• Correlating TCR clonal expansion dynamics with multiomic translational datasets to identify predictive biomarkers of response
• Building translational workflows to integrate TCR sequencing, tumor biology, and patient response data for next-generation TIL and TCR-T development

Speakers:

Víctor Albarrán Fernández

Medical Oncologist & Researcher, Cell Therapy for Solid Tumors

FCRB-IDIBAPS